Samenvatting
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
| Originele taal-2 | Engels |
|---|---|
| Pagina's (van-tot) | 1441-1458 |
| Aantal pagina's | 18 |
| Tijdschrift | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Volume | 48 |
| Nummer van het tijdschrift | 10 |
| DOI's | |
| Status | Gepubliceerd - 15 mei 2009 |
| Extern gepubliceerd | Ja |
Vingerafdruk
Duik in de onderzoeksthema's van 'Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents'. Samen vormen ze een unieke vingerafdruk.Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver